Skip to main content
SpringerLink
Log in

Tuberöse Sklerose

Everolimus als neue personalisierte Therapie – Evidenz aus der EXIT-3-Studie

  • journal club
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Referenzen

  1. Weber YG et al. Neurotherapeutics 2014; 11: 324 – 33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. French JA et al. Lancet 2016; 388: 2153 – 63

    Article  CAS  PubMed  Google Scholar 

Literatur

  • French JA, Lawson JA, Yapici Z et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388: 2153 – 63

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hertie Institut für Klinische Hirnforschung, Universitätsklinikum Tübingen, Tübingen, Deutschland

    Holger Lerche (Neurologie mit Schwerpunkt Epileptologie)

Authors
  1. Holger Lerche
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holger Lerche.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lerche, H. Everolimus als neue personalisierte Therapie – Evidenz aus der EXIT-3-Studie. InFo Neurologie 19, 26–27 (2017). https://doi.org/10.1007/s15005-017-2104-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-017-2104-6

Search

Navigation